These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28081824)

  • 1. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
    Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
    Byun YS; Lee JH; Arsenault BJ; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2015 Apr; 65(13):1286-1295. PubMed ID: 25835440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
    Szarek M; Amarenco P; Callahan A; DeMicco D; Fayyad R; Goldstein LB; Laskey R; Sillesen H; Welch KM;
    J Am Coll Cardiol; 2020 May; 75(17):2110-2118. PubMed ID: 32194196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial.
    Ganz P; Amarenco P; Goldstein LB; Sillesen H; Bao W; Preston GM; Welch KMA;
    Stroke; 2017 Dec; 48(12):3223-3231. PubMed ID: 29114094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
    Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
    J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
    Gilliland TC; Liu Y; Mohebi R; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
    J Am Coll Cardiol; 2023 May; 81(18):1780-1792. PubMed ID: 37137588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
    N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke).
    Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
    Stroke; 2018 Apr; 49(4):865-871. PubMed ID: 29511130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
    Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
    Kitagawa K; Hosomi N; Nagai Y; Kagimura T; Ohtsuki T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Nakamura M; Matsumoto M;
    J Atheroscler Thromb; 2019 May; 26(5):432-441. PubMed ID: 30318492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
    Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.